MANNKIND CORP (MNKD) Stock Fundamental Analysis
NASDAQ:MNKD - Nasdaq - US56400P7069 - Common Stock - Currency: USD
Taking everything into account, MNKD scores 5 out of 10 in our fundamental rating. MNKD was compared to 558 industry peers in the Biotechnology industry. MNKD has an average financial health and profitability rating. MNKD is evaluated to be cheap and growing strongly. This does not happen too often!
1. Profitability
1.1 Basic Checks
MNKD had positive earnings in the past year.
MNKD had a positive operating cash flow in the past year.
MNKD had negative earnings in 4 of the past 5 years.
In multiple years MNKD reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 7.23%, MNKD belongs to the best of the industry, outperforming 93.19% of the companies in the same industry.
The Return On Invested Capital of MNKD (22.19%) is better than 98.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.23% | ||
| ROE | N/A | ||
| ROIC | 22.19% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 9.96%, MNKD belongs to the top of the industry, outperforming 93.01% of the companies in the same industry.
MNKD has a Operating Margin of 27.25%. This is amongst the best in the industry. MNKD outperforms 97.31% of its industry peers.
The Gross Margin of MNKD (75.77%) is better than 83.69% of its industry peers.
In the last couple of years the Gross Margin of MNKD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.25% | ||
| PM (TTM) | 9.96% | ||
| GM | 75.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MNKD is creating value.
Compared to 1 year ago, MNKD has more shares outstanding
Compared to 5 years ago, MNKD has more shares outstanding
MNKD has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -7.48, we must say that MNKD is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -7.48, MNKD is not doing good in the industry: 67.92% of the companies in the same industry are doing better.
The Debt to FCF ratio of MNKD is 13.30, which is on the high side as it means it would take MNKD, 13.30 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MNKD (13.30) is better than 91.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 13.3 | ||
| Altman-Z | -7.48 |
ROIC/WACC2.36
WACC9.42%
2.3 Liquidity
A Current Ratio of 2.36 indicates that MNKD has no problem at all paying its short term obligations.
MNKD has a Current ratio of 2.36. This is in the lower half of the industry: MNKD underperforms 70.61% of its industry peers.
MNKD has a Quick Ratio of 2.11. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MNKD (2.11) is worse than 72.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.11 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 166.67% over the past year.
Looking at the last year, MNKD shows a very strong growth in Revenue. The Revenue has grown by 32.48%.
The Revenue has been growing by 35.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)166.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)32.48%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%18.25%
3.2 Future
MNKD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.66% yearly.
The Revenue is expected to grow by 13.58% on average over the next years. This is quite good.
EPS Next Y131.63%
EPS Next 2Y80.31%
EPS Next 3Y59.12%
EPS Next 5Y43.66%
Revenue Next Year13.13%
Revenue Next 2Y14.03%
Revenue Next 3Y13.13%
Revenue Next 5Y13.58%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 48.13, which means the current valuation is very expensive for MNKD.
Compared to the rest of the industry, the Price/Earnings ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 92.11% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.19, MNKD is valued quite expensively.
With a Price/Forward Earnings ratio of 14.80, MNKD is valued correctly.
Based on the Price/Forward Earnings ratio, MNKD is valued cheaper than 94.62% of the companies in the same industry.
MNKD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.33.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.13 | ||
| Fwd PE | 14.8 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MNKD is valued cheaply inside the industry as 96.06% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, MNKD is valued cheaply inside the industry as 92.47% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 53.64 | ||
| EV/EBITDA | 13.04 |
4.3 Compensation for Growth
MNKD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MNKD's earnings are expected to grow with 59.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.37
PEG (5Y)N/A
EPS Next 2Y80.31%
EPS Next 3Y59.12%
5. Dividend
5.1 Amount
No dividends for MNKD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.85
-0.18 (-4.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners58.52%
Inst Owner Change0%
Ins Owners1.61%
Ins Owner Change6.24%
Market Cap1.17B
Analysts86.15
Price Target9.62 (149.87%)
Short Float %8.43%
Short Ratio9.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.59%
Min EPS beat(2)-18.3%
Max EPS beat(2)-10.87%
EPS beat(4)0
Avg EPS beat(4)-77.7%
Min EPS beat(4)-246.98%
Max EPS beat(4)-10.87%
EPS beat(8)3
Avg EPS beat(8)-19.02%
EPS beat(12)5
Avg EPS beat(12)-10.38%
EPS beat(16)6
Avg EPS beat(16)-8.65%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.38%
Max Revenue beat(2)0.9%
Revenue beat(4)3
Avg Revenue beat(4)0.75%
Min Revenue beat(4)-7.78%
Max Revenue beat(4)9.49%
Revenue beat(8)6
Avg Revenue beat(8)3.43%
Revenue beat(12)9
Avg Revenue beat(12)6.54%
Revenue beat(16)12
Avg Revenue beat(16)6.34%
PT rev (1m)-8.33%
PT rev (3m)-5.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.12%
EPS NY rev (1m)0.93%
EPS NY rev (3m)0.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.86%
Revenue NY rev (1m)-1.44%
Revenue NY rev (3m)-0.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.13 | ||
| Fwd PE | 14.8 | ||
| P/S | 3.93 | ||
| P/FCF | 53.64 | ||
| P/OCF | 39.76 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.04 |
EPS(TTM)0.08
EY2.08%
EPS(NY)0.26
Fwd EY6.76%
FCF(TTM)0.07
FCFY1.86%
OCF(TTM)0.1
OCFY2.52%
SpS0.98
BVpS-0.19
TBVpS-0.22
PEG (NY)0.37
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.23% | ||
| ROE | N/A | ||
| ROCE | 27.56% | ||
| ROIC | 22.19% | ||
| ROICexc | 49.27% | ||
| ROICexgc | 51.75% | ||
| OM | 27.25% | ||
| PM (TTM) | 9.96% | ||
| GM | 75.77% | ||
| FCFM | 7.33% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score7
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 13.3 | ||
| Debt/EBITDA | 3 | ||
| Cap/Depr | 93.83% | ||
| Cap/Sales | 2.56% | ||
| Interest Coverage | 5.56 | ||
| Cash Conversion | 33% | ||
| Profit Quality | 73.61% | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.11 | ||
| Altman-Z | -7.48 |
F-Score7
WACC9.42%
ROIC/WACC2.36
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)166.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y131.63%
EPS Next 2Y80.31%
EPS Next 3Y59.12%
EPS Next 5Y43.66%
Revenue 1Y (TTM)32.48%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%18.25%
Revenue Next Year13.13%
Revenue Next 2Y14.03%
Revenue Next 3Y13.13%
Revenue Next 5Y13.58%
EBIT growth 1Y161.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y130.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y148.04%
OCF growth 3YN/A
OCF growth 5YN/A